Honest question here: why would you want a scientist as a CEO?
I’m work in the sector, and from my experience in both small and large biotech it’s not particularly common to have a “scientist” (from your definition) as a CEO. Certainly someone who understand the science well enough, and 100% with the support of an expert as their CSO.
I‘d say in terms of general attributes/experience for a CEO (not specifically referring to DXB here), having someone PHD qualified who also understands IP and business is a pretty desirable combination.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-143
-
- There are more pages in this discussion • 485 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.030(5.88%) |
Mkt cap ! $297.1M | |||
| Open | High | Low | Value | Volume |
| 51.0¢ | 54.0¢ | 49.5¢ | $2.265M | 4.358M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8490 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 204921 | 8 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |